感染症診断・検査製品の世界市場：感染症検査試薬、検査キット、診断機器、アナライザー...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 19
1.3 MARKETS SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 MARKET SIZE ESTIMATION 23
2.1.1 KEY DATA FROM SECONDARY SOURCES 27
2.1.2 KEY DATA FROM PRIMARY SOURCES 27
2.1.3 KEY INDUSTRY INSIGHTS 28
2.1.4 ASSUMPTIONS 28

3 EXECUTIVE SUMMARY 29

4 PREMIUM INSIGHTS 35
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 35
4.2 INFECTIOUS DISEASE DIAGNOSIS MARKET SNAPSHOT 36
4.3 LUCRATIVE GROWTH OPPORTUNITIES IN APAC 37
4.4 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 37
4.5 LIFE CYCLE ANALYSIS, BY REGION 38
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT 38
4.7 IDD MARKET, BY END USER 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 41
5.1.1 EVOLUTION 41
5.1.2 MARKET SEGMENTATION 42
5.2 MARKET DYNAMICS 42
5.2.1 DRIVERS 43
5.2.1.1 High prevalence rate of infectious diseases 43
5.2.1.2 Slow turnaround time of the current diagnostic cycle creating demand for rapid diagnostic procedures 44
 
5.2.1.3 New rapid diagnostic tests hold promise for improved management and control of infectious diseases 44
5.2.1.4 Growth in funding for research on infectious disease diagnostics 44
5.2.2 RESTRAINTS 45
5.2.2.1 Rising healthcare costs limiting the usage of novel infectious disease diagnostic techniques 45
5.2.2.2 Complex regulatory framework to delay approvals of new diagnostic tests 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Huge growth prospects in developing countries 46
5.2.3.2 Advances in research and development for better diagnostic procedures 46
5.2.3.3 Personalized Medicine 47
5.2.4 CHALLENGES 47
5.2.4.1 Dearth of trained professionals limiting the appropriate use of new diagnostic tests 47
5.2.4.2 Limited reimbursement for new diagnostic tests may hamper innovation 48
5.2.5 WINNING IMPERATIVE 48
5.2.5.1 Shift in focus from centralized laboratories to decentralized point-of-care testing augmenting the growth of the IDD market 48
5.2.6 BURNING ISSUE 49
5.2.6.1 Global regulatory environment limiting the clearance and marketing of infectious disease diagnostic products 49

6 INDUSTRY INSIGHTS 50
6.1 INTRODUCTION 50
6.2 STRATEGIC BENCHMARKING 50
6.3 PEST ANALYSIS 51
6.3.1 POLITICAL FACTORS 51
6.3.2 ECONOMIC FACTORS 51
6.3.3 SOCIO-CULTURAL FACTORS 51
6.3.4 TECHNOLOGICAL FACTORS 52
6.4 SUPPLY CHAIN 52
6.4.1 KEY INFLUENCERS 53
6.5 INDUSTRY INSIGHTS 53

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT 54
7.1 INTRODUCTION 55
7.2 CONSUMABLES 56
7.2.1 ASSAYS & REAGENTS 57
7.3 INSTRUMENTS & ANALYZERS 59
7.3.1 INTRODUCTION 59
7.3.2 INSTRUMENTS (OTHER THAN ANALYZERS) 59
7.4 ANALYZERS 61
7.5 SERVICES & SOFTWARE 62

8 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY APPLICATION 64
8.1 INTRODUCTION 65
8.2 HEPATITIS B 66
8.3 HEPATITIS C 68
8.4 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 69
8.5 TUBERCULOSIS (TB) 71
8.6 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) INFECTION 73
8.7 HUMAN PAPILLOMAVIRUS (HPV) INFECTION 74
8.8 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS 76
8.9 OTHER INFECTIONS 78

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 80
9.1 INTRODUCTION 81
9.2 TRADITIONAL DIAGNOSTIC TECHNOLOGIES 83
9.2.1 IMMUNODIAGNOSTICS 83
9.2.2 BIOCHEMICAL CHARACTERIZATION 85
9.2.3 MICROSCOPY 86
9.3 MOLECULAR DIAGNOSTIC TECHNOLOGIES 88
9.3.1 POLYMERASE CHAIN REACTION (PCR) 88
9.3.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 91
9.3.3 IN SITU HYBRIDIZATION 93
9.3.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 94
9.3.5 MICROARRAYS 96
9.3.6 OTHERS 99

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 101
10.1 INTRODUCTION 102
10.2 HOSPITAL LABORATORIES 103
10.3 REFERENCE LABORATORIES 105
10.4 PHYSICIANS’ OFFICE LABORATORIES 107
10.5 ACADEMIC INSTITUTE LABORATORIES 108
10.6 OTHER END USERS 109

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY GEOGRAPHY 112
11.1 INTRODUCTION 113
11.2 NORTH AMERICA 115
11.2.1 U.S. 122
11.2.2 CANADA 126
 
11.3 EUROPE 130
11.3.1 GERMANY 135
11.3.2 U.K. 135
11.3.3 REST OF EUROPE (ROE) 136
11.4 ASIA-PACIFIC 136
11.5 REST OF THE WORLD (ROW) 142

12 COMPETITIVE LANDSCAPE 146
12.1 OVERVIEW 146
12.2 MARKET SHARE ANALYSIS, GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET 147
12.3 NEW PRODUCT LAUNCHES 148
12.3.1 AGREEMENTS & PARTNERSHIPS 153
12.3.2 ACQUISITIONS 156
12.3.3 EXPANSIONS 157
12.3.4 OTHER DEVELOPMENTS 158

13 COMPANY PROFILES 162
13.1 INTRODUCTION 162
13.2 ABBOTT LABORATORIES 163
13.3 BECTON, DICKINSON & CO. 167
13.4 BIOMÉRIEUX 174
13.5 BIO-RAD LABORATORIES 179
13.6 ALERE, INC. 182
13.7 THERMO FISHER SCIENTIFIC, INC. 188
13.8 SIEMENS HEALTHCARE 193
13.9 ROCHE DIAGNOSTICS 196
13.10 DANAHER CORPORATION 199
13.11 JOHNSON & JOHNSON 201
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

14 APPENDIX 203
14.1 INSIGHTS OF INDUSTRY EXPERTS 203
14.2 DISCUSSION GUIDE 204
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 207
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 RELATED REPORTS 209